Vancomycin-resistant enterococcal bacteraemia: Is daptomycin as effective as linezolid?

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 1, 2009, Pages 175-180

  Mave, Vidya ^a   Garcia Diaz, Julia ^b   Islam, Tareq ^c   Hasbun, Rodrigo ^d  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Oschner Clinic Foundation   (United States)

^c TULANE UNIVERSITY   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Antibiotic resistance; Microbiological outcomes; Multivariable analyses; Sepsis

Indexed keywords

AMPICILLIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID;

ADULT; AGED; ANEMIA; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CANDIDEMIA; COMORBIDITY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE SEVERITY; DRUG EFFICACY; ENDOCARDITIS; ENTEROCOCCUS FAECIUM; FEMALE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; WOUND INFECTION;

ACETAMIDES; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; DAPTOMYCIN; ENTEROCOCCUS; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VANCOMYCIN RESISTANCE; YOUNG ADULT;

EID: 67249165268     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp154     Document Type: Article

References (29)

1. Wisplinghoff H, Bischoff T, Tallent SM et al. Nosocomial bloodstream infections in US hospitals: Analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-17.
2. Diaz Granados CA, Zimmer SM, Klein M et al. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: A metaanalysis. Clin Infect Dis 2005; 41: 327-33.
3. Salgado CD, Farr BM. Outcomes associated with vancomycin-resistant enterococci: A meta-analysis. Infect Control Hosp Epidemiol 2003; 24: 690-8.
4. Arias C, Murray BE. Emergence and management of drug-resistant enterococcal infections. Expert Rev Anti Infect Ther 2008; 6 637-55.
5. Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N Engl J Med 2002; 346: 867-9.
6. Ruggero KA, Schroeder LK, Schreckenberger PC et al. Nosocomial superinfections due to linezolid-resistant Enterococcus faecalis: evidence for a gene dosage effect on linezolid MICs. Diagn Microbiol Infect Dis 2003; 47: 511-3.
7. Eliopoulos GM. Quinupristin-dalfopristin and linezolid: Evidence and opinion. Clin Infect Dis 2003; 36: 473-81.
8. Tally FP, Debruin M. Development of daptomycin for Gram-positive infections. J Antimicrob Chemother 2000; 46: 523-6.
9. Laganas V, Alder J, Silverman JA. In vitro bactericidal activities of daptomycin against Staphylococcus aureus, Enterococcus faecalis are not mediated by inhibition of lipotechoic acid biosynthesis. Antimicrob Agents Chemother 2003; 47: 2682-4.
10. Woodford N. Novel agents for the treatment of resistant Gram-positive infections. Expert Opin Investica Drugs 2003; 12: 117-37.
11. Cubicin (daptomycin for injection) (package insert). Lexington, MA: Cubist Pharmaceuticals, 2003.
12. Smith PF, Booker BM, Ogundele AB et al. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center. Diagn Microbiol Infect Dis 2005; 52: 255-9.
13. Jorgensen JH, Crawford SA, Kelly CC et al. In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods. Antimicrob Agents Chemother 2003; 47: 3760-3.
14. Abb J. In vitro activities of tigecycline, daptomycin, linezolid and quinupristin/dalfopristin against glycopeptide-resistant Enterococcus faecium. Int J Antimicrob Agents 2007; 29: 358-60.
15. Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of Gram-positive bacteremia and infective endocarditis: A retrospective case series of 31 patients. Pharmacotherapy 2006; 26: 347-52.
16. Kvirikadze N, Suseno M, Vescio T et al. Daptomycin for the treatment of vancomycin resistant Enterococcus faecium bacteremia. Scand J Infect Dis 2006; 38: 290-2.
17. Furuya EY, Kubin C, Yin M et al. Daptomycin experience and comparison with linezolid for the treatment of vancomycin-resistant enterococcal bacteremia. In: Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005. Abstract K-2116; p. 379. American Society for Microbiology, Washington, DC, USA.
18. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32: 470-85.
19. Durack D, Lukes A, Bright D. New criteria for diagnosis of infective endocarditis: Utilization of specific echocardiographic findings. Am J Med 1994; 96: 200-9.
20. Charlson M, Pompei P, Ales K et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987; 40: 373-83.
21. Knaus WA, Draper EA, Wagner DP et al. APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818-29.
22. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Seventeenth Informational Supplement M100-S17. CLSI, Wayne, PA, USA, 2007.
23. Birmingham MC, Rayner CR, Meagher AK et al. Linezolid for the treatment of multidrug-resistant, Gram-positive infections: Experience from a compassionate-use program. Clin Infect Dis 2003; 36: 159-68.
24. Sakoulas G, Golan Y, Lamp K et al. Daptomycin in the treatment of bacteremia. Am J Med 2007; 120 Suppl 1: S21-7.
25. Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-65.
26. Levine DP, Lamp KC. Daptomycin experience for enterococcal endocarditis from a registry. In: Abstracts of the Ninth International Symposium on Modern Concepts in Endocarditis and Cardiovascular Infections, Heidelberg, Germany, 2007. Abstract 1518.
27. Zyvox (package insert), Kalmazoo, MI: Pharmacia, 2001.
28. Gerson SL, Kaplan SL, Bruss JB et al. Hematologic effects of linezolid: Summary of clinical experience. Antimicrob Agents Chemother 2002; 46: 2723-6.
29. Nasraway SA, Shorr AF, Kuter DJ et al. Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 2003; 37: 1609-16.